Catestatin is useful in detecting patients with stage B heart failure

Biomarkers

Volumn 16, Issue 8, 2011, Pages 691-697

  Zhu, Dan ^a   Wang, Fangfang ^a   Yu, Haiyi ^a   Mi, Lin ^a   Gao, Wei ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

B type brain natriuretic peptide (BNP); Biomarkers; Catestatin; Heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CATESTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

CHROMOGRANIN A; HEART FAILURE; HUMANS; PEPTIDE FRAGMENTS;

EID: 81855168364     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.629058     Document Type: Article

References (36)

1. Ammar H, Malani AK, Gupta C, Dobyan DC (2006). Brain natriuretic peptide, clinical reasoning, and congestive heart failure. Am J Crit Care 15:614-616.
2. Clerico A, Emdin M. (2004). Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 50:33-50. (Pubitemid 38125697)
3. Clerico A, Prontera C, Emdin M, Passino C, Storti S, Poletti R, Zyw L, Zucchelli GC. (2005). Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin Chem 51:445-447. (Pubitemid 40175816)
4. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G. (2003). Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24:1710-1718. (Pubitemid 37236859)
5. de Denus S, Pharand C, Williamson DR. (2004). Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. Chest 125:652-668. (Pubitemid 38223648)
6. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. (1986). Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy fndings. Am J Cardiol 57:450-458. (Pubitemid 16119719)
7. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Tygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). (2006). Guidelines on the management of stable angina pectoris: executive summary: Te Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 27:1341-1381. (Pubitemid 43998110)
8. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. (1990). Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82:1724-1729.
9. Gaede AH, Pilowsky PM. (2010). Catestatin in rat RVLM is sympathoexcitatory, increases barosensitivity, and attenuates chemosensitivity and the somatosympathetic refex. Am J Physiol Regul Integr Comp Physiol 299:R1538-R1545.
10. Goldberg LR, Jessup M. (2006). Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 113:2851-2860. (Pubitemid 44305298)
11. GU Dongfeng, HUANG Guangyong, HE Jiang, Wu Xigui, Duan Xiufang, Stephen MacMahon, Paul K. Whelton. (2003). Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population. Chin J Cardiol 31:3-6.
12. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005 112:e154-e235.
13. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. (2009). 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:e391-e479.
14. Mahapatra NR. (2008). Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure. Cardiovasc Res 80:330-338.
15. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK. (2005). Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115:1942-1952. (Pubitemid 40979734)
16. Mahata SK, Mahata M, Fung MM. (2010). Catestatin: A multifunctional peptide from chromogranin A. Regul Pep 165:52-62.
17. Mahata SK, Mahata M, Wakade AR, O'Connor DT. (2000). Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identifcation of amino acid residues crucial for activity. Mol Endocrinol 14:1525-1535.
18. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ. (1997). Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 100:1623-1633. (Pubitemid 27425790)
19. Maisel A. (2002). B - type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med 3(Suppl 4):S10-S17.
20. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Kjeldsen SE, Erdine S, Narkiewicz K, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Cifkova R, Dominiczak A, Fagard R, Heagerty AM, Laurent S, Lindholm LH, Mancia G, Manolis A, Nilsson PM, Redon J, Schmieder RE, Struijker-Boudier HA, Viigimaa M, Filippatos G, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Kiowski W, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Viigimaa M, Waeber B, Williams B, Zamorano JL, Te task force for the management of arterial hypertension of the European Society of Hypertension, Te task force for the management of arterial hypertension of the European Society of Cardiology. (2007). 2007 Guidelines for the management of arterial hypertension: Te Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28:1462-1536.
21. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. (2005). Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 51:2245-2251. (Pubitemid 41692566)
22. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. (2002). Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20:1335-1345. (Pubitemid 34925678)
23. Pfster R, Schneider CA. (2004). Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta 349:25-38. (Pubitemid 39311985)
24. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. (2003). Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin Chem 49:1552-1554. (Pubitemid 37011754)
25. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O'Connor DT. (2007). Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115:2271-2281. (Pubitemid 46685895)
26. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I. (1989). Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358-367.
27. thBNP Consensus Panel. (2004). BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 10:1-30.
28. Suzuki T, Yamazaki T, Yazaki Y. (2001). Te role of the natriuretic peptides in the cardiovascular system. Cardiovasc Res 51:489-494. (Pubitemid 32718597)
29. Tygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefnition of Myocardial Infarction. (2007). Universal defnition of myocardial infarction. Eur Heart J 28:2525-2538.
30. Villars PS, Hamlin SK, Shaw AD, Kanusky JT. (2004). Role of diastole in left ventricular function, I: Biochemical and biomechanical events. Am J Crit Care 13:394-403; quiz 404.
31. Wang TJ, Levy D, Benjamin EJ, Vasan RS. (2003). Te epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Intern Med 138:907-916.
32. Wang X, Xu S, Liang Y, Zhu D, Mi L, Wang G, Gao W. (2011). Dramatic changes in catestatin are associated with hemodynamics in acute myocardial infarction. Biomarkers 16:372-377.
33. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. (2003). 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21:1983-1992. (Pubitemid 38296854)
34. Wieczorek SJ, Wu AH, Christenson R, Krishnaswamy P, Gottlieb S, Rosano T, Hager D, Gardetto N, Chiu A, Bailly KR, Maisel A. (2002). A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 144:834-839. (Pubitemid 35335175)
35. Wu AH, Smith A. (2004). Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 6:355-358. (Pubitemid 38253057)
36. Yancy CW. (2004). Te prevention of heart failure in minority communities and discrepancies in health care delivery systems. Med Clin North Am 88:1347-68, xii. (Pubitemid 39178142)